<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003346</url>
  </required_header>
  <id_info>
    <org_study_id>97-124</org_study_id>
    <secondary_id>CDR0000066323</secondary_id>
    <secondary_id>NCI-H98-0014</secondary_id>
    <nct_id>NCT00003346</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>Phase I-II Trial of High-Dose Acetaminophen With Carmustine in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting&#xD;
      of acetaminophen plus carmustine in treating patients who have stage III or stage IV&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and the optimal biologic dose (OBD) of&#xD;
           high-dose acetaminophen when given alone, and the MTD of carmustine when given with&#xD;
           acetaminophen at the OBD in patients with metastatic melanoma (Phase I closed to accrual&#xD;
           3/7/2001).&#xD;
&#xD;
        -  Determine the dose of acetaminophen that results in maximal depletion of intracellular&#xD;
           glutathione in these patients.&#xD;
&#xD;
        -  Assess the antitumor activity of high-dose acetaminophen in these patients.&#xD;
&#xD;
        -  Assess the toxicity and antitumor activity of carmustine when administered with&#xD;
           high-dose acetaminophen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
        -  Phase I: (closed to accrual 3/7/2001) Patients receive a single oral dose of&#xD;
           acetaminophen, then acetylcysteine IV over 20 hours, beginning 6-8 hours after the&#xD;
           acetaminophen. This treatment is repeated 3 weeks later. On day 1 of the first&#xD;
           treatment, patients also receive carmustine IV over 1 hour, before the acetylcysteine.&#xD;
           Courses repeat every 6 weeks in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients each receive escalating doses of acetaminophen to determine the&#xD;
      optimal biological dose (OBD). The OBD is defined as the lowest dose at or preceding the&#xD;
      maximum tolerated dose (MTD) that results in maximal depletion of glutathione. The MTD is&#xD;
      defined as the dose at which no more than 1 to 6 patients experience dose-limiting toxicity&#xD;
      (DLT).&#xD;
&#xD;
      Once the OBD is established for acetaminophen, cohorts of 3-6 patients each receive&#xD;
      escalating doses of carmustine. The MTD is defined as for acetaminophen. Dose escalation does&#xD;
      not proceed until all patients are observed for 6 weeks after receiving carmustine.&#xD;
&#xD;
      Once the OBD for acetaminophen and MTD for carmustine are determined, 3 more patients are&#xD;
      treated at 3 week intervals instead of 6 weeks. If no DLT is observed, this is the dose and&#xD;
      schedule for the phase II portion of the study.&#xD;
&#xD;
        -  Phase II: A cohort of 14 patients receives oral acetaminophen and acetylcysteine IV&#xD;
           every 3 weeks. Another cohort of 14 patients receives oral acetaminophen and&#xD;
           acetylcysteine IV, then oral acetaminophen, carmustine IV, and acetylcysteine IV 3 weeks&#xD;
           later. Patients continue therapy in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-80 patients will be accrued for this study within 40 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1997</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylcysteine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV melanoma or stage III melanoma not potentially&#xD;
             curable by surgery&#xD;
&#xD;
          -  Phase I: (closed to accrual 3/7/2001) measurable or evaluable disease required&#xD;
&#xD;
          -  Phase II: At least 2 measurable subcutaneous or cutaneous metastases that are&#xD;
             accessible for biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase less than 1.5 times ULN&#xD;
&#xD;
          -  PT/PTT within normal range&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No interstitial lung disease or unexplained interstitial infiltrates on chest x-ray&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
          -  No asthma requiring treatment&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection requiring antimicrobial drugs&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No allergies to acetaminophen or acetylcysteine&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin)&#xD;
&#xD;
          -  No prior nitrosoureas&#xD;
&#xD;
          -  No prior hepatic perfusions with chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent oral contraceptives&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent vitamin, mineral, or garlic supplements&#xD;
&#xD;
          -  At least 7 days since prior garlic or alcohol&#xD;
&#xD;
          -  No concurrent treatment with medications known to affect P450 hepatic enzymes&#xD;
&#xD;
          -  No concurrent treatment with calcium channel blockers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul B. Chapman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 24, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2003</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

